Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29528695 | 0.82 | PTGS1 (0.57) | PTGS1PTGS2NPC1RAB9ACYP1A2 | |
| SCHEMBL1728538 | 0.80 | PTGS1 (0.73) | KMT2AMEN1PTGS1PTGS2NPC1 | |
| SCHEMBL29528751 | 0.78 | TGFBR1 (0.41) | PTGS1PTGS2NPC1RAB9ACYP1A2 | |
| SCHEMBL2087968 | 0.77 | PTGS1 (0.51) | KMT2AMEN1PTGS1PTGS2CNR2 | |
| SCHEMBL2085892 | 0.77 | RAB9A (0.50) | KMT2AMEN1PTGS1PTGS2NPC1 | |
| SCHEMBL2087802 | 0.76 | PTGS1 (0.46) | KMT2APTGS1PTGS2CNR2NPC1 | |
| SCHEMBL1728496 | 0.76 | PTGS1 (0.50) | KMT2APTGS1PTGS2CNR2NPC1 | |
| SCHEMBL4211423 | 0.76 | RAB9A (0.53) | KMT2AMEN1PTGS1PTGS2CNR2 | |
| SCHEMBL2086415 | 0.76 | RXFP1 (0.47) | KMT2APTGS1PTGS2CNR2NPC1 | |
| Bromide SCHEMBL2087132 | 0.76 | PTGS1 (0.50) | KMT2AMEN1PTGS1PTGS2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020061896-A1 | Imidazopyrimidine nucleoside analogues with anti-HIV activity | BIOCHEM PHARMA, INC. (CA) | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061896-A1 | Imidazopyrimidine nucleoside analogues with anti-HIV activity | TYMP, PNP, SLC29A1 | KMT2A 2945/4885MEN1 3208/4885PTGS1 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.